drugset / Trial / NCT05511948

Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos

NCT05511948

Phase 2 Completed 75 enrolled DermBiont, Inc.
RandomizedSequentialTriple-blindTreatment

Summary

This is a randomized, observer-blinded, vehicle-controlled multi-dose trial that examines the effect of twice daily application of 0.8% DBI-102 Gel, 4% Hydroquinone cream, and Vehicle Gel for 12 weeks in adults with Fitzpatrick Skin Types IV-V and a colorimeter L\* measurement between 57.8 and 46.1.

Timeline

Start
2022-08-18
Primary completion
2023-03-07
Completion
2023-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject DBI-102 Unknown 0.8 % Topical
Comparator Hydroquinone Small molecule 4 %